X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/antengene-announces-2024-interim-financial-results-highlights-progress-in-rd-and-commercialization-302229260.html
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-selinexor-approved-for-commercialization-in-malaysia-302214114.html
https://www.prnewswire.com/news-releases/xpovio-selinexor-approved-for-new-indication-in-dlbcl-in-china-bringing-a-new-treatment-option-to-patients-in-the-country-302190017.html
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-selinexor-national-health-insurance-service-approval-for-reimbursement-in-south-korea-302182936.html
https://www.prnewswire.com/news-releases/antengene-to-present-one-oral-and-four-abstracts-at-asco-2024-302154119.html
https://www.prnewswire.com/news-releases/antengene-announces-one-oral-and-three-poster-presentations-at-asco-2024-302127183.html
https://www.prnewswire.com/news-releases/antengene-presents-four-preclinical-posters-at-aacr-2024-302107397.html
https://www.prnewswire.com/news-releases/antengene-announces-full-year-2023-financial-results-highlights-clinical-progress-across-first-in-class-best-in-class-pipeline-302096838.html
https://www.prnewswire.com/news-releases/antengene-initiates-phase-ii-dose-expansion-study-of-claudin-18-2-adc-atg-022-in-china-and-australia-302094388.html
https://www.prnewswire.com/news-releases/antengene-publishes-preclinical-paper-on-pd-l14-1bb-bispecific-antibody-atg-101-in-renowned-oncology-journal-cancer-research-302093174.html
Market Place
Share 
